Why the study?
With modern disease-modifying therapies reducing sudden death in HFrEF, the need and timing for primary prevention ICDs—especially in non-ischaemic aetiology—warrant reconsideration.
Do we still need an implantable cardioverter-defibrillator for primary prevention of sudden death in patients with HFrEF on optimal modern medical therapy?
Do we still need an implantable cardioverter-defibrillator for primary prevention of sudden death in patients with HFrEF on optimal modern medical therapy?
In the era of modern foundational therapies for HFrEF that reduce sudden cardiac death, the routine use of primary prevention ICDs, particularly for non-ischaemic cardiomyopathy, warrants reconsideration.
Answers are grounded in this paper and cite their sources.
Should not yet alter primary prevention ICD decisions in HFrEF; leaves open need for prospective trials on modern therapy impact.
Sudden death is a devastating complication of heart failure (HF). Current guidelines recommend an implantable cardioverter-defibrillator (ICD) for prevention of sudden death in patients with HF and reduced ejection fraction (HFrEF) specifically those with a left ventricular ejection fraction ≤35% after at least 3 months of optimized HF treatment. The benefit of ICD in patients with symptomatic HFrEF caused by coronary artery disease has been well documented; however, the evidence for a benefit of prophylactic ICD implantation in patients with HFrEF of non-ischaemic aetiology is less strong. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA) block the deleterious actions of angiotensin II, norepinephrine, and aldosterone, respectively. Neprilysin inhibition potentiates the actions of endogenous natriuretic peptides that mitigate adverse ventricular remodelling. BB, MRA, angiotensin receptor-neprilysin inhibitor (ARNI) have a favourable effect on reduction of sudden cardiac death in HFrEF. Recent data suggest a beneficial effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing serious ventricular arrhythmias and sudden cardiac death in patients with HFrEF. So, in the current era of new drugs for HFrEF and with the optimal use of disease-modifying therapies (BB, MRA, ARNI and SGLT2i), we might need to reconsider the need and timing for use of ICD as primary prevention of sudden death, especially in HF of non-ischaemic aetiology.
No takes yet. Share an insight, caveat, or question.
Abdelhamid et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: